Long-term follow-up of retroviral vector-administered interferon-γ (IFN-γ) gene in metastatic melanoma

Nemunaitis, John; Buchanan, A; Jolly, Doug J.

doi:10.1038/sj.cgt.7700239

Cited by 3 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three of eight patients in the treatment arm that received 6 cycles of vector injections achieved a> 50% response at the injected site, with the remainder maintaining a period of stable disease at the injected site. Median survival of single-injected patients was 150 days, while the eight patients who received multiple cycles of injections had a median survival of 369 days [91]. Overall, the study showed a benefit in clinical and immunogenic response in patients receiving multiple courses of retroviral huIFN-γ vector injections; and the investigators recommended further studies to evaluate the optimal number of injections and duration of treatment; and also to study the effect of IFN-γ gene transfer in conjunction with chemotherapy or other immune therapy in patients with metastatic melanoma [92].…”

Section: Melanomamentioning

confidence: 99%

Gene therapy in interventional pulmonology: Interferon gene delivery with focus on thoracic malignancies

Kalanjeri

Sterman

2012

Curr Respir Care Rep

View full text Add to dashboard Cite

Gene therapy is a promising treatment for a variety of human diseases-particularly for malignancies-but has not been implemented into routine clinical use because sufficient delivering of therapeutic genes to effectively kill large numbers of cancer cells has proved daunting. Recently, researchers have been focusing on a method called immunogene therapy, which transfers genetic material-such as genes encoding for interferons-to trigger the patient's own immune system to fight the cancer. Mesothelioma is a particularly good target for gene therapy, because no individual treatment (surgery, chemotherapy, and/or radiation) has proven efficacious, and because mesothelioma tends to remain localized until the late stages of the disease. Even immuno-gene therapy is limited in its ability to destroy large tumors, which is why researchers are investigating combination approaches that combine traditional therapies such as surgery and chemotherapy with immunotherapy.

show abstract

Section: Melanomamentioning

confidence: 99%

Gene therapy in interventional pulmonology: Interferon gene delivery with focus on thoracic malignancies

Kalanjeri

Sterman

2012

Curr Respir Care Rep

View full text Add to dashboard Cite

show abstract

“…[9][10][11][12][13] The same proprietary vector system had been used previously to produce vectors carrying genes for clinical applications in cancer and human immunodeficiency virus (HIV) disease, and these preparations have been directly administered to more than 300 subjects without safety problems in phase 1 and phase 2 clinical trials. [14][15][16][17] However, this study was the first using intravenous administration, and, therefore, safety and tolerability were carefully monitored. The results of the trial demonstrate the safety of this retroviral vector in human subjects with hemophilia A.…”

Section: Introductionmentioning

confidence: 99%

Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion

Powell

Ragni

White

et al. 2003

Blood

203

152

View full text Add to dashboard Cite

In a phase 1 dose escalation study, 13 subjects with hemophilia A received by peripheral intravenous infusion a retroviral vector carrying a B-domain-deleted human factor VIII (hFVIII) gene. Infusions were well tolerated. Tests for replication competent retrovirus have been negative. Polymerase chain reaction (PCR) analyses demonstrate the persistence of vector gene sequences in peripheral blood mononuclear cells in 3 of 3 subjects tested. Factor VIII was measured in serial samples using both a one-stage clotting assay and a chromogenic assay. While no subject had sustained FVIII increases, 9 subjects had FVIII higher than 1% on at least 2 occasions 5 or more days after infusion of exogenous FVIII, with isolated levels that ranged from 2.3% to 19%. Pharmacokinetic parameters of exogenous FVIII infused into subjects 13 weeks after vector infusion showed an increased half-life (T 1/2 ; P < .02) and area under the curve (AUC, P < .04) compared with prestudy values. Bleeding frequency decreased in 5 subjects compared with historical rates. These results demonstrate that this retroviral vector (hFVIII(V)) is safe and, in some subjects, persists more than a year in peripheral blood mononuclear cells, with measurable factor VIII levels and with increased available FVIII activity (increased T 1/2 and AUC) after infusion of exogenous FVIII concentrate.

show abstract

Granulocyte-Macrophage Colony-Stimulating Factor Gene–Transfected Autologous Tumor Cell Vaccine: Focus on Non–Small-Cell Lung Cancer

Nemunaitis

2003

Clinical Lung Cancer

View full text Add to dashboard Cite

Long-term follow-up of retroviral vector-administered interferon-γ (IFN-γ) gene in metastatic melanoma

Abstract: Figure 1. Survival of patients (n ϭ 8) receiving multiple cycles of IFN-␥ retroviral vector (cohort B) compared with patients (n ϭ 9) receiving a single cycle (cohort A); P ϭ .0247, log-rank.

Cited by 3 publications

References 3 publications

Gene therapy in interventional pulmonology: Interferon gene delivery with focus on thoracic malignancies

Gene therapy in interventional pulmonology: Interferon gene delivery with focus on thoracic malignancies

Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion

Granulocyte-Macrophage Colony-Stimulating Factor Gene–Transfected Autologous Tumor Cell Vaccine: Focus on Non–Small-Cell Lung Cancer

Contact Info

Product

Resources

About